tetano
Editor, Senior Moderator
Epidemiol Infect
. 2024 Sep 25:152:e103.
doi: 10.1017/S0950268824000797. Omicron incidence and seroprevalence among children in Montreal, Canada, in early 2023: final results from the longitudinal EnCORE serology study
Katia Charland[SUP] 1 [/SUP], Laura Pierce[SUP] 1 [/SUP], Adrien Saucier[SUP] 1 [/SUP], Marie-Ève Hamelin[SUP] 2 [/SUP], Margot Barbosa Da Torre[SUP] 1 [/SUP], Julie Carbonneau[SUP] 2 [/SUP], Cat Tuong Nguyen[SUP] 3 [/SUP], Gaston De Serres[SUP] 4 [/SUP], Jesse Papenburg[SUP] 5 [/SUP], Guy Boivin[SUP] 2 [/SUP], Caroline Quach[SUP] 6 [/SUP], Kate Zinszer[SUP] 1 [/SUP]
Affiliations
Since early 2022, routine testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on symptoms and exposure history has largely ceased in Canada. Consequently, seroprevalence studies, particularly longitudinal studies, have become critical for monitoring the rate of incident SARS-CoV-2 infections and the proportion of the population with evidence of immunity. EnCORE is a longitudinal SARS-CoV-2 seroprevalence study comprising five rounds of serology testing from October 2020 to June 2023, in a sample of 2- to 17-year-olds (at baseline), recruited from daycares and schools in four neighbourhoods of Montreal, Canada. We report on SARS-CoV-2 incidence and seroprevalence among the 509 participants in the fifth and final round of the study. Seroprevalence of antibodies from either infection or vaccination was 98% (95 per cent confidence interval [CI]: 97, 99). The infection-acquired seroprevalence was 78% (95% CI: 73-82), and the incidence rate was 113 per 100 person-years (95% CI: 94-132), compared to the seroprevalence of 58% and the incidence rate of 133 per 100 person-years, respectively, in the fourth round of testing (mid-late 2022). Of the 131 participants newly seropositive for infection in Round 4, only 18 were seronegative for infection in Round 5 (median follow-up: 326 days).
. 2024 Sep 25:152:e103.
doi: 10.1017/S0950268824000797. Omicron incidence and seroprevalence among children in Montreal, Canada, in early 2023: final results from the longitudinal EnCORE serology study
Katia Charland[SUP] 1 [/SUP], Laura Pierce[SUP] 1 [/SUP], Adrien Saucier[SUP] 1 [/SUP], Marie-Ève Hamelin[SUP] 2 [/SUP], Margot Barbosa Da Torre[SUP] 1 [/SUP], Julie Carbonneau[SUP] 2 [/SUP], Cat Tuong Nguyen[SUP] 3 [/SUP], Gaston De Serres[SUP] 4 [/SUP], Jesse Papenburg[SUP] 5 [/SUP], Guy Boivin[SUP] 2 [/SUP], Caroline Quach[SUP] 6 [/SUP], Kate Zinszer[SUP] 1 [/SUP]
Affiliations
- PMID: 39320472
- DOI: 10.1017/S0950268824000797
Since early 2022, routine testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on symptoms and exposure history has largely ceased in Canada. Consequently, seroprevalence studies, particularly longitudinal studies, have become critical for monitoring the rate of incident SARS-CoV-2 infections and the proportion of the population with evidence of immunity. EnCORE is a longitudinal SARS-CoV-2 seroprevalence study comprising five rounds of serology testing from October 2020 to June 2023, in a sample of 2- to 17-year-olds (at baseline), recruited from daycares and schools in four neighbourhoods of Montreal, Canada. We report on SARS-CoV-2 incidence and seroprevalence among the 509 participants in the fifth and final round of the study. Seroprevalence of antibodies from either infection or vaccination was 98% (95 per cent confidence interval [CI]: 97, 99). The infection-acquired seroprevalence was 78% (95% CI: 73-82), and the incidence rate was 113 per 100 person-years (95% CI: 94-132), compared to the seroprevalence of 58% and the incidence rate of 133 per 100 person-years, respectively, in the fourth round of testing (mid-late 2022). Of the 131 participants newly seropositive for infection in Round 4, only 18 were seronegative for infection in Round 5 (median follow-up: 326 days).